Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors

Journal of Medicinal Chemistry

Volumn 57, Issue 14, 2014, Pages 5995-6007

  Vuorinen, Anna ^a   Engeli, Roger ^b   Meyer, Arne ^b   Bachmann, Fabio ^b   Griesser, Ulrich J ^a   Schuster, Daniela ^a   Odermatt, Alex ^b  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Swiss Centre for Applied Human Toxicology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTRONE; OXIDOREDUCTASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; HUMAN; HUMAN CELL; HYDROGEN BOND; LIGAND BINDING; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESTRADIOL DEHYDROGENASES; HEK293 CELLS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; USER-COMPUTER INTERFACE;

EID: 84904959820     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5004914     Document Type: Article

References (65)

1. Reginster, J.-Y.; Burlet, N. Osteoporosis: A still increasing prevalence Bone 2006, 38, S4-S9
2. Glaser, D.; Kaplan, F. Osteoporosis. Definition and clinical presentation Spine (Philadelphia) 1997, 22 (24 suppl) 12S-16S
3. Compston, J. E. Sex Steroids and Bone Phys. Rev. 2001, 81, 419-447
4. Riggs, B.; Khosia, S.; Melton, L. r. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men J. Bone Miner. Res. 1998, 13, 763-773
5. Chin, K.-Y.; Ima-Nirwana, S. Sex steroids and bone health status in men Int. J. Endocrinol. 2012, 2012, 208719
6. Michael, H.; Härkönen, P. L.; Väänänen, H. K.; Hentunen, T. A. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption J. Bone Miner. Res. 2005, 20, 2224-2232
7. Kanis, J. A.; McCloskey, E. V.; Johansson, H.; Cooper, C.; Rizzoli, R.; Reginster, J.-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporosis Int. 2012, 24, 23-57
8. Lewiecki, E. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis J. Womens Health 2009, 18, 1615-1626
9. Marjoribanks, J.; Farguhar, C.; Roberts, H.; Lethaby, A. Long term hormone therapy for perimenopausal and postmenopausal women Cochrane Database Syst. Rev. 2012, 11, CD004143
10. Janssen, J. M. M. F.; Bland, R.; Hewison, M.; Coughtrie, M. W. H.; Sharp, S.; Arts, J.; Pols, H. A. P.; van Leeuwen, J. P. T. M. Estradiol Formation by Human Osteoblasts via Multiple Pathways: Relation with Osteoblast Function J. Cell. Biochem 1999, 75, 528-537
11. Dong, Y.; Qiu, Q. Q.; Debear, J.; Lathrop, W. F.; Bertolini, D. R.; Tamburini, P. P. 17β-Hydroxysteroid dehydrogenases in human bone cells J. Bone Miner. Res. 1998, 13, 1539-1546
12. Takeyama, J.; Sasano, H.; Suzuki, T.; Iinuma, K.; Nagura, H.; Andersson, S. 17β-Hydroxysteroid dehydrogenase types 1 and 2 in human placenta: An immunohistochemical study with correlation to placental development J. Clin. Endocrinol. Metab. 1998, 83, 3710-3715
13. Mustonen, M. V.; Isomaa, V. V.; Vaskivuo, T.; Tapanainen, J.; Poutanen, M. H.; Stenbäck, F.; Vihko, R. K.; Vihko, P. T. Human 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle J. Clin. Endocrinol. Metab. 1998, 83, 1319-1324
14. Elo, J. P.; Akinola, L. A.; Poutanen, M.; Vihko, P.; Kyllönen, A. P.; Lukkarinen, O.; Vihko, R. Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate Int. J. Cancer 1996, 66, 37-41
15. Mustonen, M. V. J.; Poutanen, M. H.; Kellokumpu, S.; de Launoit, Y.; Isomaa, V. V.; Vihko, R. K.; Vihko, P. T. Mouse 17β-hydroxysteroid dehydrogenase type 2 mRNA is predominantly expressed in hepatocytes and in surface epithelial cells of the gastrointestinal and urinary tracts J. Mol. Endocrinol. 1998, 20, 67-74
16. Bagi, C. M.; Wood, J.; Wilkie, D.; Dixon, B. Effect of 17β-hydroxysteroid dehydrogenase type 2 inhibitor on bone streght in ovariectomized cynomolgus monkeys J. Musculoskeletal Neuronal Interact. 2008, 8, 267-280
17. Wu, L.; Einstein, M.; Geissler, W. M.; Chan, H. K.; Elliston, K. O.; Andersson, S. Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme posessing 20α-hydroxysteroid dehydrogenase activity J. Biol. Chem. 1993, 268, 12964-12639
18. Puranen, T. J.; Kurkela, R. M.; Lakkakorpi, J. T.; Poutanen, M. H.; Itäranta, P. V.; Melis, J. P. J.; Ghosh, D.; Vihko, R. K.; Vihko, P. T. Characterization of molecular and catalytic properties of intact and truncated human 17β-hydroxysteroid dehydrogenase type 2 enzymes: Intracellular localization of the wild-type enzyme in the endoplasmic reticulum Endocrinology 1999, 140, 3334-3341
19. Labrie, F.; Luu-The, V.; Lin, S.-X.; Labrie, C.; Simard, J.; Breton, R.; Bélanger, A. The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology Steroids 1997, 62, 148-158
20. Wu, X.; Lukacik, P.; Kavanagh, K. L.; Oppermann, U. SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone action Mol. Cell. Endocrinol. 2007, 265-266, 71-76
21. Kavanagh, K. L.; Jörnvall, H.; Persson, B.; Oppermann, U. The SDR superfamily: Functional and structural diversity within a family of metabolic and regulatory enzymes Cell. Mol. Life Sci. 2008, 65, 3895-3906
22. Xu, K.; Al-Soud, Y. A.; Wetzel, M.; Hartmann, R. W.; Marchais- Oberwinkler, S. Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors Eur. J. Med. Chem. 2011, 46, 5978-5990
23. Wetzel, M.; Marchais-Oberwinkler, S.; Hartmann, R. W. 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold Bioorg. Med. Chem. 2011, 19, 807-815
24. Wood, J.; Bagi, C. M.; Akuche, C.; Bacchiocchi, A.; Baryza, J.; Blue, M.-L.; Brennan, C.; Campbell, A.-M.; Choi, S.; Cook, J. H.; Conrad, P.; Dixon, B. R.; Ehrlich, P. P.; Gane, T.; Gunn, D.; Joe, T.; Johnson, J. S.; Jordan, J.; Kramss, R.; Liu, P.; Levy, J.; Lowe, D. B.; McAlexander, I.; Natero, R.; Redman, A. M.; Scott, W. J.; Town, C.; Wang, M.; Wang, Y.; Zhang, Z. 4,5-Disubstituted cis -pyrrolidinones as inhibitors of type II 17β-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate Bioorg. Med. Chem. Lett. 2006, 16, 4965-4968
25. Oster, A.; Klein, T.; Werth, R.; Kruchten, P.; Bey, E.; Negri, M.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Novel estrone mimetics with high 17β-HSD1 inhibitory activity Bioorg. Med. Chem. 2010, 18, 3494-3505
26. Marchais-Oberwinkler, S.; Xu, K.; Wetzel, M.; Perspicace, E.; Negri, M.; Meyer, A.; Odermatt, A.; Möller, G.; Adamski, J.; Hartmann, R. W. Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis J. Med. Chem. 2012, 56, 167-181
27. Al-Soud, Y. A.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2 Arch. Pharm. 2012, 345, 610-621
28. Wermuth, C. G.; Ganellin, C. R.; Lindberg, P.; Mitscher, L. A. Glossary of terms used in medicinal chemistry (IUPAC Recommendations) Pure Appl. Chem. 1998, 70, 1129-1143
29. Gao, Q.; Yang, L.; Zhu, Y. Pharmacophore based drug design approach as a practical process in drug discovery Curr. Comput.-Aided Drug Des. 2010, 6, 37-49
30. Schuster, D.; Waltenberger, B.; Kirchmair, J.; Distinto, S.; Markt, P.; Stuppner, H.; Rollinger, J. M.; Wolber, G. Predicting cyclooxygenase inhibition by three-dimentional pharmacophoric profiling. Part I: Model generation, validation and applicability in ethnopharmacology Mol. Inf. 2010, 1, 79-90
31. Bydal, P.; Auger, S.; Poirier, D. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: Structure-activity relationships Steroids 2004, 69, 325-342
32. Vuorinen, A.; Nashev, L. G.; Odermatt, A.; Rollinger, J. M.; Schuster, D. Pharmacophore model refinement for 11β-hydroxysteroid dehydrogenase inhibitors: Search for modulators of intracellular glucocorticoid concentrations Mol. Inf. 2014, 33, 15-25
33. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeabilityy in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
34. Organic Chemistry Portal. OSIRIS Property Explorer; Actelion Pharmaceuticals Ltd., Gewerbestrasse 16, 4123 Allschwil, Switzerland.
35. Atanasov, A. G.; Tam, S.; Rocken, J. M.; Baker, M. E.; Odermatt, A. Inhibition of 11 beta-hydroxysteroid dehydrogenase type 2 by dithiocarbamates Biochem. Biophys. Res. Commun. 2003, 308, 257-62
36. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A Specific Mechanism of Nonspecific Inhibition J. Med. Chem. 2003, 46, 4265-4272
37. Odermatt, A.; Kratschmar, D. V. Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: An overview Mol. Cell. Endocrinol. 2012, 350, 168-86
38. Geissler, W. M.; Davis, D. L.; Wu, L.; Bradshaw, K. D.; Patel, S.; Mendonca, B. B.; Elliston, K. O.; Wilson, J. D.; Russell, D. W.; Andersson, S. Male pseudohermaphroditism caused by mutations of testicular 17beta-hydroxysteroid dehydrogenase 3 Nat. Genet. 1994, 7, 34-39
39. Halperin, J. A.; Natarajan, A.; Aktas, H.; Fan, Y.-H. C., Preparation of 3-3-di-substituted oxindoles as inhibitors of translation initiation. Patent WO 2005080335 A1, January 9, 2005.
40. Xu, F.; Xu, H.; Wang, X.; Zhang, L.; Wen, Q.; Zhang, Y.; Xu, W. Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III Bioorg. Med. Chem. 2014, 22, 1487-1495
41. Kotelevtsev, Y.; Brown, R. W.; Fleming, S.; Kenyon, C.; Edwards, C. R. W.; Seckl, J. R.; Mullins, J. J. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2 J. Clin. Invest. 1999, 103, 683-689
42. Wang, M. Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 in Antidiabetic Therapy. In Diabetes-Perspectives in Drug Therapy; Schwanstecher, M., Ed.; Springer: Berlin, 2011; Vol. 203, pp 127-146.
43. Andersson, S.; Geissler, W. M.; Patel, S.; Wu, L. The molecular biology of androgenic 17β-hydroxysteroid dehydrogenases J. Steroid Biochem. Mol. Biol. 1995, 53, 37-39
44. Koh, E.; Noda, T.; Kanaya, J.; Namiki, M. Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues Prostate 2002, 53, 154-159
45. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindayalov, I. N.; Bourne, P. E. The Protein Data Bank Nucl. Acids. Res. 2000, 28, 235-242
46. Mazumdar, M.; Fournier, D.; Zhu, D. W.; Cadot, C.; Poirier, D.; Lin, S. X. Binary and ternary crystal structure analyses of a novel inhibitor with 17β-HSD type 1: a lead compound for breast cancer therapy Biochem. J. 2009, 424, 357-366
47. Baell, J. B.; Holloway, G. A. New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays J. Med. Chem. 2010, 53, 2719-2740
48. Lilienkampf, A.; Karkola, S.; Alho-Richmond, S.; Koskimies, P.; Johansson, N.; Huhtinen, K.; Vihko, K.; Wähälä, K. Synthesis and biological evaluation of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors based on a thieno[2,3- d ]pyrimidin-4(3 H)-one core J. Med. Chem. 2009, 52, 6660-6671
49. Allan, G. M.; Lawrence, H. R.; Cornet, J.; Bubert, C.; Fischer, D. S.; Vicker, N.; Smith, A.; Tutill, H. J.; Purohit, A.; Day, J. M.; Mahon, M. F.; Reed, M. J.; Potter, B. V. L Modification of estrone at the 6, 16, and 17 positions: Novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 2006, 49, 1325-1345
50. Schuster, D.; Nashev, L. G.; Kirchmair, J.; Laggner, C.; Wolber, G.; Langer, T.; Odermatt, A. Discovery of nonsteroidal 17β-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries J. Med. Chem. 2008, 51, 4188-4199
51. Schuster, D.; Kowalik, D.; Kirchmair, J.; Laggner, C.; Markt, P.; Aebischer-Gumy, C.; Ströhle, F.; Möller, G.; Wolber, G.; Wilckens, T.; Langer, T.; Odermatt, A.; Adamski, J. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening J. Steroid Biochem. Mol. Biol. 2011, 125, 148-161
52. Fischer, D. S.; Allan, G. M.; Bubert, C.; Vicker, N.; Smith, A.; Tutill, H. J.; Purohit, A.; Wood, L.; Packham, G.; Mahon, M. F.; Reed, M. J.; Potter, B. V. L E-ring modified steroids as novel potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 J. Med. Chem. 2005, 48, 5749-5770
53. ChemBioDraw Ultra, 12.0; CambridgeSoft, 1986-2010.
54. OMEGA, 2.2.3; OpenEye Scientific Software, Santa Fe, NM.
55. Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the protein databank and Cambridge Structural Database J. Chem. Inf. Model 2010, 50, 572-584
56. Hawkins, P. C. D.; Nicholls, A. Conformer generation with OMEGA: Learning from the data set and the analysis of failures J. Chem. Inf. Model 2012, 52, 2919-2936
57. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters J. Chem. Inf. Model 2005, 45, 160-169
58. Wolber, G.; Dornhofer, A. A.; Langer, T. Efficient overlay of small organic molecules using 3D pharmacophores J. Comput.-Aided Mol. Des. 2006, 20, 773-788
59. Pipeline Pilot; Accelrys Software Inc., 2010.
60. DiscoveryStudio, 3.0; Accelrys Software Inc., 2005-2010.
61. SciFinder; American Chemical Society, 2013.
62. Berthold, M.; Cebron, N.; Dill, F.; Gabriel, T.; Kötter, T.; Meinl, T.; Ohl, P.; Sieb, C.; Thiel, K.; Wiswedel, B. KNIME: The Konstanz Information Miner. In Data Analysis, Machine Learning and Applications; Preisach, C.; Burkhardt, H.; Schmidt-Thieme, L.; Decker, R., Eds.; Springer: Berlin, 2008; pp 319-326.
63. Saubern, S.; Guha, R.; Baell, J. B. KNIME Workflow to Assess PAINS Filters in SMARTS Format. Comparison of RDKit and Indigo Cheminformatics Libraries Mol. Inf. 2011, 30, 847-850
64. Kratschmar, D. V.; Vuorinen, A.; Da Cunha, T.; Wolber, G.; Classen-Houben, D.; Doblhoff, O.; Schuster, D.; Odermatt, A. Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11β-hydroxysteroid dehydrogenase type 2 J. Steroid Biochem. Mol. Biol. 2011, 125, 129-142
65. Nashev, L. G.; Schuster, D.; Laggner, C.; Sodha, S.; Langer, T.; Wolber, G.; Odermatt, A. The UV-filter benzophenone-1 inhibits 17β-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals Biochem. Pharmacol. 2010, 79, 1189-1199